Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CHKA | P35790 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HRH1 | P35367 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL955257 | 0.86 | HRH1 (0.32) | USP2SMN1; SMN2TDP1HRH1 | |
| SCHEMBL3553188 | 0.81 | — | — | |
| SCHEMBL5110502 | 0.79 | USP2 (0.30) | USP2 | |
| SCHEMBL5069712 | 0.76 | — | — | |
| SCHEMBL2914797 | 0.76 | ALDH1A1 (0.44) | USP2SMN1; SMN2TDP1CA2CHKA | |
| SCHEMBL4347815 | 0.74 | — | — | |
| SCHEMBL2918689 | 0.73 | CXCR4 (0.41) | USP2SMN1; SMN2TDP1CA2CHKA | |
| SCHEMBL5030028 | 0.72 | ALDH1A1 (0.47) | USP2SMN1; SMN2TDP1CA2CHKA | |
| SCHEMBL336574 | 0.71 | CA2 (0.46) | USP2SMN1; SMN2TDP1CA2CHKA | |
| SCHEMBL3769647 | 0.71 | CXCR4 (0.42) | USP2SMN1; SMN2TDP1CA2CHKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10472420-B2 | Immune response modifier conjugates | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2019-11-12 | — | — | US | disclosed |
| US-20150141625-A1 | IMMUNE RESPONSE MODIFIER CONJUGATES | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2015-05-21 | — | — | US | disclosed |
| US-8951528-B2 | Immune response modifier conjugates | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2015-02-10 | — | — | US | disclosed |
| US-8846710-B2 | Method of preferentially inducing the biosynthesis of interferon | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-09-30 | — | — | US | disclosed |
| US-8658666-B2 | Substituted imidazoquinolines and imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-02-25 | — | — | US | disclosed |
| US-8378102-B2 | Oxime and hydroxylamine substituted thiazolo[4,5-c] ring compounds and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2013-02-19 | — | — | US | disclosed |
| US-20100240693-A1 | Oxime and Hydroxylamine Substituted Thiazolo [4,5-C] Ring Compounds and Methods | COLEY PHARMACEUTICAL GROUP, INC (US) | 2010-09-23 | — | — | US | disclosed |
| US-20100152230-A1 | HYDROXY SUBSTITUTED 1H-IMIDAZOPYRIDINES AND METHODS | PFIZER INC. | 2010-06-17 | — | — | US | disclosed |
| US-20080015184-A1 | Urea Substituted Imidazopyridines, Imidazoquinolines, and Imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2008-01-17 | — | — | US | disclosed |
| US-20070259907-A1 | ARYL AND ARYLALKYLENYL SUBSTITUTED THIAZOLOQUINOLINES AND THIAZOLONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152230-A1 | HYDROXY SUBSTITUTED 1H-IMIDAZOPYRIDINES AND METHODS | IL4, IL2, IL4I1 | USP2 4272/4885SMN1; SMN2 2868/4885TDP1 2513/4885 |
| US-20150141625-A1 | IMMUNE RESPONSE MODIFIER CONJUGATES | IFNG, CD74, MYD88 | USP2 234/4885SMN1; SMN2 4620/4885TDP1 3389/4885 |
| US-20070259907-A1 | ARYL AND ARYLALKYLENYL SUBSTITUTED THIAZOLOQUINOLINES AND THIAZOLONAPHTHYRIDINES | IL2, TSLP, IFNG | USP2 3879/4885SMN1; SMN2 4726/4885TDP1 3897/4885 |
| US-20080015184-A1 | Urea Substituted Imidazopyridines, Imidazoquinolines, and Imidazonaphthyridines | IL2, EIF2AK2, IL4 | USP2 514/4885SMN1; SMN2 3238/4885TDP1 3026/4885 |
| US-20100240693-A1 | Oxime and Hydroxylamine Substituted Thiazolo [4,5-C] Ring Compounds and Methods | IL4, IL2, TH | USP2 4183/4885SMN1; SMN2 3463/4885TDP1 2495/4885 |
| US-10472420-B2 | Immune response modifier conjugates | IFNG, CD74, MYD88 | USP2 234/4885SMN1; SMN2 4620/4885TDP1 3389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.